FINWIRES · TerminalLIVE
FINWIRES

TD Cowen Upgrades Genmab to Buy Rating, Boosts PT

By

TD Cowen on Wednesday upgraded Danish biotechnology company Genmab (GMAB.CO) to buy from hold and increased its price target to 2,851 Danish kroner from 2,019 kroner.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Related Articles